News & Updates

The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

Retreatment with infliximab (IFX) appears safe and effective in nearly a third of patients with Crohn’s disease (CD), independent of the reason for prior discontinuation, results of a study have shown.

Adjuvant therapy with 5-fluorouracil and low-molecular weight heparin (LMWH) is not superior to placebo in the prevention of proliferative vitreoretinopathy (PVR) in eyes with rhegmatogenous retinal detachment (RRD), reports a study.

Use of proton pump inhibitors (PPIs) helps prevent upper gastrointestinal (GI) bleeding in patients using oral anticoagulants, reveals a study.

Patient outcomes are not significantly different between the use of biologics fact sheet and the ibdandme.org (IBD&me), a freely available, unbranded, interactive decision aid, a study has shown. High satisfaction is noted with both resources.

The administration of restrictive, compared with standard, intravenous (IV) fluid therapy to patients with septic shock in the intensive care unit (ICU) did not result in a reduction in mortality risk, according to results of the CLASSIC* trial.